Wall Street's Deal Rush and the Antitrust Storm Ahead

Wall Street's immediate reaction to the Democratic sweep defied simple predictions. Rather than pulling back on merger and acquisition activity, investment banks are reportedly racing to close megadeals before the new majority is fully seated — betting that transactions signed, structured, and filed with regulators in the next sixty to ninety days may be evaluated under the current enforcement regime before new agency leadership can reshape priorities.

Understanding why requires a brief primer on how antitrust law actually works. The Sherman Act of 1890 does not define a monopoly by size alone. It requires both that a company possesses monopoly power in a relevant market — the ability to control prices or exclude competition — and that it willfully acquired or maintained that power through exclusionary conduct, not merely by outcompeting rivals. Courts have generally held that market share above 70 percent creates a presumption of monopoly power, but a company with 65 percent share and genuinely competitive behavior can be entirely legal, while one with 40 percent share and predatory pricing practices can be in violation.

The incoming Democratic regulatory appointees at the FTC and DOJ Antitrust Division are expected to revive the more conduct-focused, structural-remedies approach characteristic of the Biden administration. Warren's warning that companies should brace for 'serious' probes signals that the Senate intends to be an active participant through hearings, subpoenas, and the confirmation process for agency heads.

Healthcare mergers draw particular scrutiny: hospital system consolidations, pharmacy benefit manager deals, and insurance conglomerate acquisitions have been building for years, and there is a substantial academic and legal literature arguing that consolidation in those markets has directly contributed to higher patient costs. That argument carries political potency in an environment where, as Hamilton's Kansas victory demonstrated, living-cost concerns drove voting behavior.

Yet S&P futures rose Monday morning despite the regulatory uncertainty — because markets also anticipate that a Democratic Senate brings infrastructure spending conversations, potential pharmaceutical pricing negotiations, and reduced exposure to some of the more disruptive deregulatory policy swings that created their own forms of market uncertainty. Markets prize predictability, and a clear regulatory framework can be preferable to constant policy flux.